Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.
The transcatheter repair clip beat the established medical therapy on the primary composite endpoint, setting up a battle with a rival company for a $5 billion market.
Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023.
The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.
With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.
Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.
Incyte Corporation’s Phase III LIMBER-304 clinical trial has come to an end following a third-party investigation that forecasted poor results.
[et_pb_section bb_built=”1″][et_pb_row][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ fullwidth=”off” specialty=”off”][et_pb_row][et_pb_column type=”1_4″][et_pb_team_member _builder_version=”3.0.99″ image_url=”https://convitgroup.com/wp-content/uploads/2018/02/Jacinto-Convit.jpg” name=”Jacinto Convit García” position=”Investigador” background_layout=”light”] “You have to love and let yourself go. Hatred kills, love heals ” September 11, 1913 – Mayo12, 2014 [/et_pb_team_member][/et_pb_column][et_pb_column type=”3_4″][et_pb_text _builder_version=”3.0.99″ background_layout=”light”] Jacinto Convit García was a Venezuelan physician and scientist, known for developing a vaccine to fight leprosy and his …
